The model incorporates specific data from MRI exams with patient risk factors to predict whether a person is likely to develop clinically significant prostate cancer.
Finely tuned, pre-trained large language models are beginning to reliably translate image content into text, but are they ready to take on medical images?
Researchers tracked data from more than 400,000 patients for a new meta-analysis, presenting their findings in the Journal of the American Heart Association.
PAD and CLI patients who show signs of coronary heart disease may benefit from early treatment, according to a new study of nearly 4 million hospitalizations.
Although these tools have proven themselves valuable in numerous settings, they must be used with caution, especially by patients and nonradiologist providers who may be seeking clarification on imaging reports.
The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.
![An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.](/sites/default/files/styles/240x220/public/2024-04/screen_shot_2024-04-26_at_10.55.10_am.png.webp?itok=ZMT_brpB)
